Abstracts tagged "T cells and autoimmune diseases"

Abstract Number: 2569 • 2017 ACR/ARHP Annual Meeting
Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Cell Function and Its Selective Deficiency in T Lymphocytes Leads to Autoimmunity and Lupus-like Nephritis
Vaishali R. Moulton¹, Takayuki Katsuyama¹, Hao Li¹, Michael W. Mosho¹, Andrew R. Gillooly² and George C. Tsokos¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit defects in signaling including a reduced expression of the CD3 zeta signaling chain, and…
Abstract Number: 3028 • 2015 ACR/ARHP Annual Meeting
CD1d Regulates iNKT Cell Autoreactivity
Meng Zhao^1,2 and Mitchell Kronenberg², ¹Medicine, UC-San Diego, La Jolla, CA, ²Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA
Background/Purpose: Invariant Natural Killer T (iNKT) cells are a unique population of lymphocytes that express an invariant TCR alpha chain, and react to lipid antigens…
Abstract Number: 2739 • 2014 ACR/ARHP Annual Meeting
SHP-1 Regulates the Activation Threshold of iNKT Cells
Meng Zhao^1,2 and Mitchell Kronenberg³, ¹Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²Medicine, UC-San Diego, La Jolla, CA, ³La Jolla Institute for Allergy and Immunology, La Jolla, CA
Background/Purpose Autoreactive invariant Natural Killer T (iNKT) cells have been implicated in several rheumatic diseases, including Systemic lupus erythematosus and Rheumatoid arthritis. iNKT cells are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].